BiotechTube
Airway Therapeutics

Airway Therapeutics

Cincinnati, United States· Est.
airwaytherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Airway Therapeutics is a private, clinical-stage biotech founded in 2011 and based in Cincinnati, Ohio. The company is advancing zelpultide alfa, a recombinant version of human surfactant protein D (SP-D), as a foundational immune-modulating therapy. With a Phase 2b/3 program in BPD for preterm neonates actively progressing and regulatory support from the EMA, the company is positioning its platform for broader applications in acute and chronic inflammatory lung diseases. Airway represents a focused investment in a novel biologic approach to unmet needs in respiratory medicine.

RespiratoryInflammatory DiseasesInfectious Diseases

Technology Platform

Recombinant human surfactant protein D (SP-D) platform designed to modulate inflammation and enhance infection clearance.

Funding History

2
Total raised:$18M
Grant$3M
Series A$15M

Opportunities

The lead program addresses a high-unmet need in BPD with no approved pharmacologic therapies, creating a potential first-in-class market opportunity.
The platform's dual mechanism against inflammation and infection offers potential expansion into large markets like ARDS and pulmonary fibrosis.
Regulatory support, evidenced by EMA PDCO agreement, de-risks the pediatric development pathway.

Risk Factors

High clinical development risk as the novel biologic advances into larger Phase 2b/3 trials.
Financial risk as a pre-revenue, private company dependent on external funding for costly multinational trials.
Platform concentration risk, with the company's value tied to a single asset, zelpultide alfa.

Competitive Landscape

In BPD, competition is limited to supportive care and off-label use of corticosteroids/diuretics, positioning zelpultide alfa as a potential first-in-class therapy. In target adult indications (ARDS, PF), the landscape is more crowded with approved anti-fibrotic and anti-inflammatory drugs, requiring demonstration of superior or complementary efficacy.

More companies in Biologics / Biosimilars →More companies in United States →